Annis Gardner Whiting Capital Advisors LLC Takes $672,000 Position in Natera, Inc. $NTRA

Annis Gardner Whiting Capital Advisors LLC acquired a new position in Natera, Inc. (NASDAQ:NTRA) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 4,175 shares of the medical research company’s stock, valued at approximately $672,000.

Several other institutional investors also recently bought and sold shares of NTRA. Main Management ETF Advisors LLC increased its stake in Natera by 1.7% in the 2nd quarter. Main Management ETF Advisors LLC now owns 4,398 shares of the medical research company’s stock worth $743,000 after purchasing an additional 72 shares during the period. Yousif Capital Management LLC boosted its stake in shares of Natera by 4.5% during the third quarter. Yousif Capital Management LLC now owns 1,682 shares of the medical research company’s stock valued at $271,000 after purchasing an additional 72 shares during the period. Gries Financial LLC grew its holdings in shares of Natera by 4.0% in the third quarter. Gries Financial LLC now owns 1,904 shares of the medical research company’s stock worth $306,000 after purchasing an additional 74 shares during the last quarter. Blue Trust Inc. increased its stake in shares of Natera by 23.1% in the third quarter. Blue Trust Inc. now owns 431 shares of the medical research company’s stock worth $69,000 after buying an additional 81 shares during the period. Finally, Earned Wealth Advisors LLC increased its stake in shares of Natera by 4.7% in the third quarter. Earned Wealth Advisors LLC now owns 1,952 shares of the medical research company’s stock worth $314,000 after buying an additional 88 shares during the period. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Natera Stock Down 1.8%

NTRA opened at $235.93 on Thursday. Natera, Inc. has a 52 week low of $125.38 and a 52 week high of $256.36. The stock has a market cap of $32.63 billion, a PE ratio of -103.03 and a beta of 1.62. The business has a 50 day moving average of $235.78 and a 200-day moving average of $193.03.

Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Friday, November 7th. The medical research company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.25). The firm had revenue of $592.18 million during the quarter, compared to analysts’ expectations of $514.55 million. Natera had a negative return on equity of 25.07% and a negative net margin of 14.61%.Natera’s revenue for the quarter was up 34.7% on a year-over-year basis. During the same period in the previous year, the company earned ($0.26) earnings per share. Equities analysts anticipate that Natera, Inc. will post -1.49 EPS for the current year.

Analyst Ratings Changes

Several brokerages have weighed in on NTRA. UBS Group increased their price target on shares of Natera from $218.00 to $280.00 and gave the company a “buy” rating in a research report on Tuesday, November 18th. BNP Paribas Exane raised shares of Natera to a “hold” rating and set a $172.00 price objective for the company in a research note on Monday, October 27th. TD Cowen reissued a “buy” rating on shares of Natera in a research note on Wednesday, January 7th. Piper Sandler boosted their price target on Natera from $220.00 to $230.00 and gave the company an “overweight” rating in a report on Tuesday, November 11th. Finally, Barclays upped their price target on Natera from $230.00 to $270.00 and gave the company an “overweight” rating in a research report on Monday, December 15th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $249.20.

Insider Buying and Selling at Natera

In related news, insider Solomon Moshkevich sold 293 shares of the stock in a transaction dated Wednesday, January 21st. The shares were sold at an average price of $235.00, for a total value of $68,855.00. Following the completion of the transaction, the insider directly owned 144,699 shares in the company, valued at $34,004,265. This trade represents a 0.20% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Michael Burkes Brophy sold 37,175 shares of Natera stock in a transaction dated Wednesday, January 21st. The shares were sold at an average price of $242.54, for a total transaction of $9,016,424.50. Following the transaction, the chief financial officer directly owned 64,123 shares of the company’s stock, valued at approximately $15,552,392.42. This trade represents a 36.70% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 499,569 shares of company stock valued at $111,419,899 over the last 90 days. 5.63% of the stock is owned by corporate insiders.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.